

VEGF-A/VEGFR-1: a painful astrocyte-mediated signaling blocked by the anti-VEGFR-1 mAb D16F7

Laura Micheli^{1*}, Carmen Parisio^{1*}, Elena Lucarini¹, Alessia Vona¹, Alessandra Toti¹, Alessandra Pacini², Tommaso Mello³, Serena Boccella⁴, Flavia Ricciardi⁴, Sabatino Maione⁴, Grazia Graziani⁵, Pedro Miguel Lacal⁶, Paola Failli¹, Carla Ghelardini¹, Lorenzo Di Cesare Mannelli^{1§}

*These authors contributed equally

1. *Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and Toxicology Section, Università degli Studi di Firenze, Viale G. Pieraccini 6, 50139, Florence, Italy*
2. *Department of Experimental and Clinical Medicine - DMSC – Anatomy and Histology Section, Università degli Studi di Firenze, L. go Brambilla 3, 50134, Florence, Italy*
3. *Department of Biomedical, Experimental and Clinical Sciences, Università degli Studi di Firenze, Viale G. Pieraccini 6, 50139, Florence, Italy*
4. *Department of Experimental Medicine, Section of Pharmacology, Università degli Studi della Campania “Luigi Vanvitelli”, Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy*
5. *Department of Systems Medicine, Università di Roma “Tor Vergata”, Via Montpellier 1, 00133, Rome, Italy*
6. *IDI-IRCCS, Via Monti di Creta 104, 00167, Rome, Italy*

§Corresponding author, email address: lorenzo.mannelli@unifi.it. Address: Viale Pieraccini 6, 50139 Florence, Italy. Phone: +390552758395

Abstract

Chemotherapy-induced neuropathic pain is a clinically relevant adverse effect of several anticancer drugs leading to dose reduction or therapy discontinuation. The lack of knowledge about the mechanisms of neuropathy development and pain chronicization makes chemotherapy-induced neuropathic pain treatment an unmet medical need. In this context, the vascular endothelial growth factor A (VEGF-A) has emerged as a neurotoxicity biomarker in a model of chemotherapy-induced neuropathy, and its decrease has been related to pain relief. Aim of this study was to clarify the VEGF-A-dependent pain signaling in the CNS for individuating new targeted therapeutic approaches. In mice, the intrathecal infusion of VEGF-A induced a dose-dependent noxious hypersensitivity mediated by the VEGF receptor 1 (VEGFR-1) as demonstrated by pharmacological and genetic tools. In electrophysiological study, VEGF-A stimulated the spinal nociceptive neurons activity through VEGFR-1. In the dorsal horn of the spinal cord, VEGF-A increased in astrocytes of animals affected by neuropathy suggesting this cell population as a source of the potent pain mediator. Accordingly, the selective knockdown of astrocytic VEGF-A, by shRNA_{Amir}, blocked the development of oxaliplatin-induced neuropathic pain. Besides, the anti-VEGFR-1 mAb D16F7 (previously described as anticancer) effectively relieved neuropathic pain induced by chemotherapeutic agents. In conclusion, astrocyte-released VEGF-A is a new player in the complex neuron-glia network that oversees physiological and pathological pain and D16F7 mAb rises as a potent pain killer strategy.

Running title: VEGF-A/VEGFR-1 block for pain relief

Keywords: VEGF-A, VEGFR-1, chemotherapy-induced neuropathic pain, astrocytes, D16F7 mAb, biomarker

Introduction

Persistent pain induced by the neurotoxic effects of anticancer chemotherapy (hereafter referred to as chemotherapy-induced neuropathic pain, CINP) is a kind of pure neuropathic hypersensitivity. Direct nervous tissue damages and a complex maladaptive response of peripheral and central nervous systems orchestrate a painful syndrome that keeps on after therapy discontinuation and beyond cancer resolution (Di Cesare Mannelli *et al*, 2013; Miltenburg & Boogerd, 2014; Ibrahim & Ehrlich, 2020).

Studying the role of stem cells in relieving neuropathic pain, we recently showed that the plasma concentration of vascular endothelial growth factor A (VEGF-A) was enhanced in rats repeatedly treated with oxaliplatin. Stem cells were able to control pain and normalize VEGF-A suggesting a possible role of the growth factor as pain mediator (Di Cesare Mannelli *et al*, 2018).

VEGF-A is a large anti-parallel homodimeric peptide that belongs to the “Cys-loop” superfamily of proteins. It is mainly known as a pro-angiogenic factor mediating blood vessel formation, vascular permeability, endothelial cell proliferation, differentiation, leakage, migration, survival, and motility (Iyer & Acharya, 2011). Alternative splicing of the *Vegfa* gene selectively removes intron regions and joins specific combinations of exons to generate distinct VEGF-A isoforms. Differing in respect to their length, isoforms are designated as VEGF_{xxx} where xxx represents the number of amino acids present in the final protein sequence (the prototypical transcript VEGF₁₆₅ as well as the other commonly represented VEGF₁₁₁, VEGF₁₂₁, VEGF₁₄₅, VEGF₁₈₉, and VEGF₂₀₆; (Peach *et al*, 2018). A major site of alternative splicing occurs at exon 8, whereby proximal splicing results in the VEGF_{xxx}a forms and distal splicing generates the VEGF_{xxx}b isoforms containing exon 8b (Stevens & Oltean, 2018). VEGF_{xxx}a isoforms (that only differ from VEGF_{xxx}b in the six amino acids found at their C termini) are considered to be “pro-angiogenic”, whereas VEGF_{xxx}b isoforms have been reported to have “anti-angiogenic” properties (Peach *et al*, 2018), although this description does not reflect the whole functions of VEGF-A_{xxx}b’s (Ved *et al*, 2018). Interestingly, in quiescent vessels, a higher proportion of total VEGF-A is represented by VEGF₁₆₅b (Woolard *et al*, 2004).

Despite its discovery as an angiogenic factor, from an evolutionary perspective VEGF-A emerged in the CNS of primitive organisms that lacked an established vasculature, suggesting a vessel-independent activity (Ruiz de Almodovar *et al*, 2009; Ponnambalam & Alberghina, 2011). Indeed, growing evidence indicates a diverse range of effects of VEGF-A on neural cells during development and in adulthood (Ruiz de Almodovar *et al*, 2009; Lange *et al*, 2016). It promotes CNS perfusion and induces direct neurotrophic effects in normal and pathological conditions and, as a permeability factor, VEGF-A modulates blood-brain barrier (BBB) functionality (Argaw *et al*, 2012; Licht & Keshet, 2013).

Cellular responses to VEGF-A are mainly driven by their cognate receptors, VEGFR-1 and -2, belonging to the class IV receptor tyrosine kinase family. The well-known VEGFR-2 plays essential roles in angiogenesis (Nakayama *et al*, 2013), as well as it mediates the neuroprotective effects of VEGF-A (Taiana *et al*, 2014; Verheyen *et al*, 2013). VEGFR-1 has a higher affinity for VEGF-A than VEGFR-2 but it shows decreased tyrosine kinase activity. VEGFR-1 is widely expressed also in non-endothelial cells and its soluble forms exhibit a negative modulatory activity on VEGFR-2 effects (Failla *et al*, 2018; Peach *et al*, 2018; Seki *et al*, 2018); nevertheless, its biological functions remain largely undefined.

The role of VEGF-A in pain signalling is debated as conflicting literature data suggest both algescic (Lin *et al*, 2010; Selvaraj *et al*, 2015; Hamilton *et al*, 2016; Lee *et al*, 2019) and analgesic effects (Verheyen *et al*, 2012; Hulse *et al*, 2014; Ved *et al*, 2018; Hu *et al*, 2019; Verheyen *et al*, 2013). The present work intends to dissect the pain modulatory properties of VEGF-A in the CNS in physiological and neuropathic conditions by using preclinical *in vivo* models of CINP. Moreover, the role of the different receptor subtypes in pain signalling and the potential of the VEGF-A/VEGFRs system as target for relieving pain was explored.

Results

Nociceptive effect of VEGFRs selective ligands infused in spinal cord

To study the spinal impact of VEGF-A signalling modulation on pain threshold in mice, we firstly evaluated the effect of the most expressed isoform VEGF_{165b}. After i.t. administration, pain sensitivity was measured as latency response to a cold stimulus (Cold plate test). As shown in Fig. 1A, VEGF_{165b} (3, 10 and 30 ng, in bolus in a total volume of 5 µl) dose-dependently reduced pain threshold with a long-lasting effect starting 30 min after injection that completely disappeared only after 6 h, resembling its effect observed in rats (Di Cesare Mannelli *et al*, 2018). To note, VEGF_{165a} (1, 3 and 30 ng, i.t.) evoked similar dose-dependent nociceptive effects (Supplementary Fig. S1). Since VEGF₁₆₅ isoforms may interact with both VEGFR-1 and VEGFR-2, in order to explore the implications of the receptor types in pain modulation, we also tested the effect of placental growth factor 2 (PlGF-2) and VEGF-E, which are specific VEGFR-1 and VEGFR-2 agonists, respectively (Cudmore *et al*, 2012). As shown in Fig. 1B and 1C, both PlGF-2 and VEGF-E (3, 10 and 30 ng, i.t.) significantly reduced the licking latency of animals challenged on a cold surface (Cold Plate test), even if PlGF-2 showed a profile similar to VEGF_{165b} while VEGF-E exhibited a lower efficacy. Interestingly, the selective VEGFR-1 blockade by the anti-VEGFR-1 mAb D16F7 (1 µg, i.t.), in the absence of VEGF_{165b}, did not significantly alter pain threshold at microgram dose (Fig. 1D). On the contrary, nanogram dose of the anti-murine VEGFR-2 mAb DC101 (1 and 6 ng, i.t.)

induced hypersensitivity (Fig. 1E) and this effect was blocked by D16F7 mAb (10 and 100 ng; Fig. 1F). In this test, non-specific mouse IgG (1 μ g), used as control, was inactive. These findings suggested that the nociceptive effects evoked by VEGF₁₆₅b were the result of VEGFR-1 stimulation. Furthermore, algescic effects induced by the DC101 mAb were likely due to the antibody-dependent displacement of the endogenous VEGF-A from VEGFR-2, thus making it available for binding to VEGFR-1; this hypothesis was further demonstrated by the loss of the effect when the anti-VEGFR-1 mAb D16F7, was administered together with DC101.




Figure 1. Nociceptive effect of VEGFRs selective ligands infused in spinal cord.

The pain threshold was measured by the Cold plate test over time after the i.t. injection of compounds. Effect of (A) VEGF₁₆₅b (n=7), (B) the selective VEGFR-1 agonist PlGF-2 (n=5), (C) the selective VEGFR-2 agonist VEGF-E (n=5), (D) the selective anti-VEGFR-1 antibody D16F7 (n=7) or a murine control IgG (n=5) and (E) the selective anti-VEGFR-2 antibody DC101 (n=5). (F) Effect of DC101 in mice pre-treated (15 min before) with D16F7. Each value represents the mean $\pm$ SEM. *P<0.05 and **P<0.01 vs vehicle-treated animals; °P<0.01 vs DC101 6 ng treated animals. The analysis of variance was performed by One-way ANOVA. A Bonferroni's significant difference procedure was used as post hoc comparison.

Hypersensitivity-induced by VEGF-A signalling modulators is due to VEGFR-1 activation

The hypothesis that VEGFR-1 activation is required for VEGF₁₆₅b-mediated nociception was demonstrated by crossing the combinations of receptor agonists and antagonists. Both selective agonists, PlGF-2 and VEGF-E (Cai *et al*, 2017; Park *et al*, 1994; Persico *et al*, 1999; Meyer, 1999), share the same binding sites of VEGF-A on the corresponding receptors. At variance with DC101 mAb which is a competitive antagonist of VEGF-A and VEGF-E for VEGFR-2 binding (Falcon *et al*, 2016), D16F7 mAb is a non-competitive antagonist since it interacts with VEGFR-1 at a site

different from that used by the receptor ligands (Graziani *et al*, 2016; Laca & Graziani, 2018). Consistently with our hypothesis, the algescic effects of VEGF₁₆₅b are blocked by D16F7 mAb (Fig. 2A). A similar profile was obtained also for the VEGFR-1 ligand PlGF-2 (Fig. 2B) as well as for the VEGFR-2 ligand VEGF-E (Fig. 2C). DC101 mAb used at the highest non-algescic dose (but able to selectively block VEGFR-2) (Falcon *et al*, 2016) did not block the effect of both VEGF₁₆₅b and PlGF-2, but further exacerbated VEGF-E hypersensitivity (Supplementary Fig. S2). These findings confirmed the pivotal role of VEGFR-1 in pain signalling which is directly activated by the selective agonist PlGF-2 or by the exogenously added (Fig. 2A) or endogenously present VEGF-A (Fig. 2C) displaced from VEGFR-2. Moreover, the selective knockdown of VEGFR-1 or VEGFR-2 by siRNA further validated the specificity of the VEGFR-1-mediated mechanism (Fig. 2D-F). The silencing of VEGFR-1 completely blocked the effects of VEGF₁₆₅b, PlGF-2 and VEGF-E (Fig. 2E) whereas the silencing of VEGFR-2 did not alter the algescic properties of the ligands (Fig. 2F).




Figure 2. Hypersensitivity-induced by VEGF-A signalling modulators is due to its interaction with VEGFR-1.

The response to a thermal stimulus (Cold plate test) was recorded after i.t. infusion of different VEGFR ligands (30 ng) preceded (15 min before) or not by the anti-VEGFR-1 mAb D16F7 (100 ng) or vehicle: (A) VEGF₁₆₅b ± D16F7 (n=5), (B) PlGF-2 ± D16F7 (n=5), (C) VEGF-E ± D16F7 (n=5). (E - F) Effects of VEGFRs ligands (i.t.) in mice undergone a selective knockdown of VEGFR-1 (D, n=5) or VEGFR-2 (E, n=5) at the lumbar level of the spinal cord by siRNA. (D) Representative western blot images and densitometric analysis showing the expression of VEGFR-1 or VEGFR-2 in the lumbar section of the spinal cord after the siRNAs administration (n=5). Each value represents the mean ± SEM. **P<0.01 vs vehicle + vehicle-treated animals; °°P<0.01 vs vehicle + VEGFRs ligands-treated animals. The analysis of variance was performed by One-way ANOVA. A Bonferroni's significant difference procedure was used as post hoc comparison.

VEGF₁₆₅b increases the activity of spinal nociceptive neurons by VEGFR-1 activation

To investigate the effect of the spinal application of VEGF₁₆₅b on the hyperexcitability of spinal nociceptive specific (NS) neurons, *in vivo* electrophysiological experiments were performed. The results relate to NS neurons (one cell recorded from each animal per treatment) localized at a depth of 0.7-1.0 mm from the surface of the spinal cord. This cell population was characterized by a mean rate of basal firing of 0.015 ± 0.002 spikes/sec and only cells showing this pattern were chosen for the experiment. Spontaneous and noxious-evoked (mechanical stimulation) activity of NS neurons was measured after spinal application of VEGF₁₆₅b preceded or not by treatment with the anti-VEGFR-1 mAb D16F7 to investigate the involvement of VEGF-A receptor subtype. Representative ratemeters of the results obtained with VEGF₁₆₅b in the absence or presence of D16F7 mAb are shown in Fig. 3A and 3B, respectively. In mice pre-treated with vehicle (DMSO in 0.9% NaCl), VEGF₁₆₅b (3 ng/5 μ l) spinal application induced an increase in spinal electrical activity as compared to baseline levels (100%). In particular, NS neurons showed a variation of spontaneous activity compared to baseline of $217.05 \pm 29.2\%$ as well as a noxious-evoked activity with frequency of $234 \pm 30.9\%$ and duration of $316.2 \pm 27.2\%$, starting from 25 min post VEGF₁₆₅b (Fig. 3A, C-E). The spinal VEGF₁₆₅b-induced hypersensitivity was mainly mediated by VEGFR-1 rather than VEGFR-2 activation. Indeed, electrophysiological recordings revealed that spinal pre-application of D16F7 mAb (100 pg/5 μ l) significantly prevented the increase of spontaneous and noxious-induced activity of NS neurons resulting in a pattern similar to basal (Fig. 3B, C-E). D16F7 (100 pg/5 μ l) alone was not able to affect either spontaneous or evoked activity of NS neurons (Fig. 3B). On the contrary, DC101 at 30 and 100 pg, showed a pro-nociceptive effect on NS spinal activity *per se* (Supplementary Fig. S3, representative ratemeters). In fact, post-injection level of either spontaneous ($187.3 \pm 17.7\%$ at 100 pg and $151.1 \pm 6.9\%$ at 30 pg) or noxious pressure-evoked firing rates (frequency: $212.6 \pm 27\%$ at 100 pg and $152.9 \pm 6.9\%$ at 30 pg; duration: $235.7 \pm 25.3\%$ at 100 pg and $119.7 \pm 8.6\%$ at 30 pg) were significantly higher respect to the baseline, in a dose-dependent manner. Overall, these results further confirmed the involvement of VEGFR-1 in VEGF-A-induced electrophysiological changes of NS.




Figure 3. VEGF165b increases spontaneous and noxious-evoked activity of NS neurons by VEGFR-1.

Representative ratemeters showing spontaneous and noxious-evoked activity of NS neurons after spinal application of VEGF165b alone or in combination with D16F7 mAbs (A and B, respectively); black arrows indicate the noxious stimulation on the mouse hind-paw. Mean $\pm$ S.E.M population data of spinal cord application of VEGF165b (3 ng/5 μ l) in the presence of vehicle (DMSO in 0.9% NaCl), or D16F7 (100 pg/5 μ l) on firing rate of spontaneous activity (C), frequency (D) and duration of evoked activity (E) of NS neurons in CD1 mice. Black arrows indicate vehicle, D16F7 or VEGF165b spinal application. Each point represents the mean of 5 different mice per group (one neuron recorded per each mouse). # P <0.05, ## P <0.01 and ### P <0.001 indicate statistically difference vs baseline; * P <0.05, ** P <0.01 and *** P <0.001 indicate statistically difference vs vehicle + VEGF165b. One-way ANOVA followed by Dunnett's multiple comparison post-hoc test was performed for statistical significance within groups. Two-way ANOVA followed by Bonferroni post-hoc test was used for comparison between groups.

VEGF-A and VEGFR-1 localization in the spinal cord of naïve mice

Immunofluorescence analysis was performed in the dorsal horn of the spinal cord to study VEGF-A and VEGFR-1 expression profile in the nervous cells. VEGF-A immunoreactivity in astrocytes (as colocalization with GFAP; Fig. 4A and 4D) was significantly higher in comparison to microglia (Iba1 positive cells) and neurons (NeuN positive cells) (Fig. 4B, 4C and 4D). As expected, VEGF-A staining is strictly related to vessel structure (Fig. 4) since its expression was observed both on

endothelial cells and astrocyte endfeet (Lange *et al*, 2016). To better investigate this aspect, we compared the co-localization of VEGF-A with GFAP and RECA-1, a marker of endothelial cells. As shown in Fig. 5A, it is possible to identify separate areas of VEGF-A/GFAP and VEGF-A/RECA-1 colocalization. Furthermore, VEGF-A expression in astrocytes was also confirmed by confocal microscopy. Results shown in Fig. 5B and 5C confirm the colocalization of VEGF-A with GFAP and Aquaporin 4 (AQP4, a marker of astrocytic endfeet). Indeed, the Van Steensel's cross-correlation function (CCF) clearly shows that VEGF-A co-localizes with GFAP and AQP4 in cellular structures with an estimated diameter of $1.00 \pm 0.11 \mu\text{m}$ and $1.28 \pm 0.12 \mu\text{m}$ (CCF at FWHM, mean $\pm$ SD, Supplementary Figure S4C and S4F), respectively, which are compatible with the size of astrocytic processes. Collectively, these analyses demonstrate the presence of a VEGF-A pool in astrocytes.

As regards the expression of VEGFR-1, it was more prominent in neurons than in astrocytes (Fig. 4E, 4F and 4G).





Figure 4. Cellular localization of VEGF-A and VEGFR-1 in the spinal cord of naïve mice.

246 VEGF-A immunoreactivity was analysed in the spinal cord dorsal horn of naïve mice. Colocalization with GFAP-
247 positive astrocytes (A, n=9), Iba1 positive microglia (B, n=8) and NeuN-positive neurons (C, n=7) was evaluated and
248 quantified (D). Immunofluorescence co-staining of VEGFR-1 in the dorsal horn with GFAP (E, n=7) or NeuN (F, n=8)
249 positive cells, and quantitative analysis (G). Scale bar: 100 μ m. Each value represents the mean $\pm$ SEM. §§P<0.01 vs
250 VEGF-A + Iba1 and VEGF-A + NeuN. ^P<0.01 vs VEGFR1 + GFAP.



Staining	PCC	M1	M2	Li's ICQ
GFAP/VEGF-A	0.38 $\pm$ 0.04	0.42 $\pm$ 0.06	0.33 $\pm$ 0.04	0.20 $\pm$ 0.01
AQP4/VEGF-A	0.78 $\pm$ 0.01	0.62 $\pm$ 0.08	0.87 $\pm$ 0.03	0.35 $\pm$ 0.01

252

253 **Figure 5. Colocalization analysis of VEGF-A and RECA-1, GFAP or AQP4 in the spinal cord of naïve mice.**

254 A) VEGF-A immunoreactivity was analysed in the spinal cord dorsal horn of naïve mice in comparison to RECA-
255 1-positive endothelial cells and GFAP-positive astrocytes; arrows indicate the presence of VEGF-A in astrocytes; scale
256 bar: 100 μ m. B and C). Deconvolved confocal z-stacks shown as maximum intensity projection. Arrows indicate points
257 of interest. B) Representative GFAP and VEGF-A z-stack. C) Representative GFAP and Aquaporin-4 z-stack. Table).
258 Colocalization parameters are given as mean $\pm$ SEM (n=8), PCC= Pearson's Correlation Coefficient; M1=Mander's
259 M1; M2= Mander's M2; Li's ICQ= Li's Intensity Correlation Quotient. Colocalization graph are shown in
260 Supplementary Figure S4.

261

VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy

A painful neuropathy was reproduced in mice by a repeated treatment with oxaliplatin (Cavaletti *et al*, 2001; Di Cesare Mannelli *et al*, 2017). After 2 weeks of treatment, when hypersensitivity was developed, VEGF-A immunoreactivity significantly increased in dorsal horns of the spinal cord in comparison to control animals (Fig. 6A and Supplementary Fig. S5). The increment was specifically confirmed in astrocytes when colocalization of VEGF-A expression in GFAP-positive cells was measured (Fig. 6B, 6C and 6D). As regards VEGFRs, VEGFR-2 expression increased in the spinal cord of oxaliplatin-treated mice as revealed by western blot, on the contrary VEGFR-1 was unaffected by chemotherapy (Supplementary Fig. S6).




Figure 6. VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy.

(A) Representative images and quantitative analysis of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control (n=13). (B-D) Colocalization analysis of VEGF-A and GFAP in the different groups, a quantitative analysis was reported (D) (vehicle + vehicle, n=13; oxaliplatin + vehicle, n=12). Scale

277 *bar: 100 μ m; insert: 50 μ m. Each value represents the mean $\pm$ SEM. * P <0.05 vs vehicle + vehicle group. The analysis*
 278 *of variance was performed by One-way ANOVA. A Bonferroni's significant difference procedure was used as post hoc*
 279 *comparison.*

280

281 *VEGF-A silencing in astrocytes prevents neuropathic pain*

282 To study the influence of astrocytic VEGF-A modulation on pain signaling, we selectively silenced
 283 VEGF-A in spinal astrocytes by injecting an AAV1-GFAP-eGFP-VEGFA-shRNAmir. The vector
 284 was bilaterally injected at the lumbar and thoracic levels of the spinal cord 2 weeks before the first
 285 oxaliplatin treatment. As shown in Fig. 7A, 4 weeks after injection, the vector fluorescence
 286 colocalized with GFAP-positive cells inducing a significant decrease of VEGF-A expression (Fig.
 287 7B). The pain threshold measurements by employing thermal (Cold plate test) and mechanical (Von
 288 Frey test) non-noxious stimuli over time showed a significant prevention of hypersensitivity
 289 development during the 2 weeks of oxaliplatin treatment in the group that received the VEGF-A
 290 specific shRNAmir in comparison to scrambled- and vehicle-treated mice (Fig. 7C and 7D). To
 291 verify the lack of neurological and motor alterations which could interfere with pain behavior
 292 recordings, VEGF-A shRNAmir and scrambled-treated mice motor functionality and exploratory
 293 activity were evaluated by the Hole board test. No alterations were highlighted with the exception
 294 of a higher exploratory activity on day 3 of oxaliplatin protocol (Supplementary Table S2).

295




Figure 7. VEGF-A silencing in astrocytes prevents neuropathic pain.

AAV1-GFAP-eGFP-VEGFA-shRNAir was injected in the spinal cord to decrease VEGF-A expression in astrocytes. (A) Representative image of eGFP and GFAP fluorescence in a whole section at lumbar level, scale bar: 100 μ m. Higher magnifications were reported to visualize the colocalization, scale bar: 50 μ m (n=4). (B) Representative western blot images and densitometric analysis showing the expression of VEGF-A in the lumbar section of the spinal cord after the vector administration (n=4, blot of samples obtained from 2 animals of each group are shown). Pain threshold was evaluated by (C) Cold plate and (D) Paw pressure test (n=5). Each value represents the mean $\pm$ SEM. * P <0.05 and ** P <0.01 vs vehicle + vehicle; ^ P <0.05 and ^^ P <0.01 vs scrambled + oxaliplatin group. The analysis of variance was performed by One-way ANOVA. A Bonferroni's significant difference procedure was used as post hoc comparison.

The anti VEGFR1 mAb D16F7 relieves pain in different models of CINP

To evaluate the anti-hypersensitivity potential of D16F7, we tested its activity against neuropathic pain induced by anticancer drugs. In the already described oxaliplatin model, D16F7 was infused i.t. (100 ng, 1 μ g and 5 μ g) showing a significant, dose-dependent, increase of the pain threshold both after thermal and mechanical non-noxious and noxious stimulation, respectively. Hypersensitivity was fully counteracted (up to control values) from 30 min to 3 h after treatment (Fig. 8A and 8B). On the contrary, the anti VEGFR-2 antibody DC101 (100 pg i.t.) was ineffective (data not shown). Interestingly, D16F7 mAb maintained its efficacy also when systemically injected by the i.p. route (1, 5, 15 and 25 mg kg⁻¹). It was active starting from the dose 5 mg kg⁻¹, the onset of the analgesic effect was observed at 60 min and efficacy maintained up to 120 min (Supplementary Fig. S7A and S7B). The pain relieving properties of D16F7 mAb seems to be not limited to the oxaliplatin neurotoxicity since it was also effective in mice become hypersensitive after treatment with the neurotoxic anticancer drugs vincristine and paclitaxel. In both models, D16F7 mAb (1 and 5 μ g, i.t.) was active between 30 min and 3 h (Fig. 8C-F) in the Cold plate and Paw pressure tests with a particular efficacy when the pain response was evoked by thermal stimuli (Fig. 8C and 8E). In paclitaxel-treated mice 15 μ g D16F7 mAb dosed i.t. was effective till to 5 h (Fig. 8E).




Figure 8. D16F7 mAb reduces pain in different models of chemotherapy-induced neuropathy. Effect of D16F7 mAb evaluated by (A) Cold plate and (B) Paw pressure tests in a mouse model of oxaliplatin-induced neuropathy after i.t. injection (A, B, n=6). (C, D) Effect of D16F7 mAb after i.t. administration in vincristine-treated mice stimulated with thermal (C) or mechanical (D) stimuli (n=6). (E, F) Effect of D16F7 after i.t. administration in paclitaxel-treated mice stimulated with thermal (E) or mechanical (F) stimuli (n=6). Each value represents the mean $\pm$ SEM. ** P <0.01 vs vehicle + vehicle-treated animals; ^ P <0.05 and ^ P <0.01 vs chemotherapeutic drugs + vehicle-treated animals. The analysis of variance was performed by One-way ANOVA. A Bonferroni's significant difference procedure was used as post hoc comparison.

Discussion

Our data indicate that VEGF-A evokes pain through VEGFR-1 activation at the CNS site in physiological and pathological conditions. In particular, CINP is sustained by a spinal VEGF-A release from astrocytes that can be counteracted by the anti-VEGFR-1 mAb D16F7.

Using recombinant VEGF_{165b}, the most represented VEGF-A isoform, we showed an increase of the electrophysiological activity of nociceptive neurons in the spinal cord with a consequent, significant decrease of the pain threshold (hypersensitivity was similarly induced by the VEGF_{165a} isoform). These data are in agreement with our previous results (Di Cesare Mannelli *et al*, 2018) and with the peripheral pro-nociceptive effect of VEGF-A demonstrated by Selvaraj and colleagues (Selvaraj *et al*, 2015) after an intraplantar injection as well as with the VEGF-A increase in synovial fluid of subjects afflicted by osteoarticular pain (Hamilton *et al*, 2016). Furthermore, in peripheral nervous system, anti-VEGF-A mAb treatment was found to alleviate neuropathic pain induced by the chronic constriction injury of the sciatic nerve (Lin *et al*, 2010). In our hands, both the selective VEGFR-1 agonist PlGF-2 and the selective VEGFR-2 agonist VEGF-E induced nociception after i.t. infusion. In addition, the selective anti-VEGFR-2 mAb DC101 induced hypersensitivity whereas the selective anti-VEGFR-1 mAb D16F7 did not. Based on these data, it could be hypothesized that VEGFR-1 selectively mediates pain, either directly stimulated by the exogenously added PlGF-2 or by the endogenously produced VEGF-A displaced from VEGFR-2 by VEGF-E or by the competitive DC101 mAb. In this context, it is worth noting that D16F7 mAb is a non-competitive inhibitor that hampers VEGFR-1 activation without affecting ligand binding (Graziani *et al*, 2016; Lacal & Graziani, 2018). The involvement of VEGFR-1 in algnesia induced by VEGF-A was confirmed by the ability of D16F7 mAb to block the nociceptive effects of all the agonists as well as of DC101. Furthermore, the knockdown of VEGFR-1 prevented VEGF_{165b}, PlGF-2 and VEGF-E effects, strongly indicating the pivotal role of this receptor in the spinal pain pathway. These data are in agreement with those described by Selvaraj and colleagues (Selvaraj *et al*, 2015) in the peripheral nervous system where VEGF-A induced nociceptive sensitization via VEGFR-1. Consistently with behavioural data, electrophysiological experiments revealed that VEGF_{165b} spinal application, caused a strongly increase of both spontaneous and evoked activity of NS neurons in naïve animals. In particular, the increased responsiveness to mechanical noxious stimuli of NS neurons induced by VEGF_{165b} spinal microinjection suggests that low doses of this compound were able to induce a central sensitisation, similarly to the neuropathic pain condition induced by nerve injury. In this context, the pre-application of D16F7 prevented the VEGF-A-induced neuronal hyperexcitability, ruling out the contribution of this receptor in VEGF-A-mediated painful effects.

In the normal healthy CNS, VEGF-A regulates microvascular density, vessel permeability, and maintains endothelial cell fenestration in the choroid plexus, stimulates neural stem cell

proliferation and promotes neurogenesis (Lange *et al*, 2016). In pathological conditions (besides beneficial vascular effects), it safeguards stressed neurons, induces axon extension and branching, and promotes synaptic plasticity; furthermore, VEGF-A triggers proliferation, survival and migration of astrocytes and stimulates expression of trophic factors by astrocytes and microglia (Ruiz de Almodovar *et al*, 2009; Lange *et al*, 2016). Glia cells play a crucial role in the maladaptive plasticity of the nervous system in chronic pain and, particularly, in neuropathies (Scholz & Woolf, 2007). Activated by neuronal damage or by signals from periphery, glia participate in pain development and chronicization, amplifying the excitatory synaptic microenvironment (Stockstill *et al*, 2018; Di Cesare Mannelli *et al*, 2015). Released soluble factors, like cytokines and growth factors, possess a direct nociceptive effect (Sommer *et al*, 2018). Among the latter, NGF, BDNF, GDNF, etc, seem unable to separate the neuroprotective effect from the algic one probably following the evolutionary positive alarm role of physiological pain (Alles & Smith, 2018; Nencini *et al*, 2018; Garraway & Huie, 2016). In this context, the nociceptive effect of VEGF-A is not surprising. Neuropathies induced by trauma to a peripheral nerve (Hulse *et al*, 2014) or by chemotherapy (Di Cesare Mannelli *et al*, 2018) are characterized by enhanced spinal concentration of VEGF-A. The present results show, as expected (Lange *et al*, 2016), a relevant spinal VEGF-A concentration in the vessel structure; nevertheless, the existence of an *extra*-endothelial component was verified and confirmed. In comparison to microglia and neurons, astrocytes of healthy mice showed the highest amount of VEGF-A, which was clearly distinguishable from the vascular component. The repeated treatment with oxaliplatin up to the development of painful neuropathy significantly enhanced the presence of the growth factor in astroglia. The selective VEGF-A knockdown in dorsal horn astrocytes at the lumbar and thoracic levels of the spinal cord strongly reduced oxaliplatin-dependent neuropathic pain suggesting astrocytic VEGF-A as a relevant component of the pain signalling orchestrated by glia. Furthermore, enhanced concentrations of VEGF-A can also lead to other pathological alterations related to neuropathies like an increased BBB permeability (Di Cesare Mannelli *et al*, 2014; Branca *et al*, 2018; Montague-Cardoso *et al*, 2020). As low maintenance levels of VEGF-A are necessary for the integrity of the BBB, high levels can alter permeability and compromise CNS (Argaw *et al*, 2012; Licht & Keshet, 2013). The hypoxia inducible factor-1 driven by IL-1 promotes VEGF-A release from astrocytes that induces down-regulation or loss of endothelial tight proteins claudin-5 and occludin, determining a loss of BBB function (Argaw *et al*, 2012; Chapouly *et al*, 2015) by mechanisms involving VEGFR-1 (Lee *et al*, 2019). On the other hand, the increase in VEGF-A levels in neurotoxic conditions is generally related to hypoxia, clearly demonstrated in diabetic- as well as in chemotherapy-induced neuropathies (Ved *et al*, 2018; Rojas *et al*, 2018; Di Cesare Mannelli *et al*, 2018), suggesting the

need of improving vascular functions (Lange *et al*, 2016). The rescue role of VEGF-A is also based on its extra-vascular neuroprotective and neurodegenerative properties mainly due to the activation of the VEGFR-2. VEGF-A stimulates the migration and survival of Schwann cells (Schratzberger *et al*, 2000), it protects neurons against chemotherapy-induced cytotoxicity via activation of VEGFR-2 and MEK1/2 and inhibition of caspase-3 (Beazley-Long *et al*, 2013). VEGF-A-signalling through VEGFR-2 leads to the protection of dorsal root ganglion sensory neurons in models of drug (paclitaxel) or hyperglycaemia-induced neuropathies, through induction of Heat Shock Protein 90 deacetylation and increase of Bcl-2 (Verheyen *et al*, 2012, 2013). The loss of endothelial VEGFR-2 signalling leads to tissue alteration in the dorsal horn and the development of hyperalgesia whereas neuronal overexpression of VEGFR-2 in mice reduced the sensitivity to paclitaxel-induced peripheral neuropathy (Verheyen *et al*, 2012). This outcome seems to be related to neuroprotective effects and, accordingly, we showed an increase of VEGFR-2 spinal expression in oxaliplatin-treated mice that could be considered an adaptive response to the damage. On the contrary, the acute stimulation of VEGFR-2 does not directly interfere with pain.

Our data show that VEGF-A induces pain by selectively activating the VEGFR-1, which is expressed on spinal sensory neurons. A dichotomy between the pro-algesic VEGFR-1-signaling and the protective VEGFR-2-signaling is suggested, offering the possibility to relieve pain through a target that conserves the neuroprotective effects of the endogenous VEGF-A. In this view, the selective anti-VEGFR-1 mAb D16F7 induced a potent pain-relieving effect against nociception triggered by VEGF-A or PlGF-2 as well as against neuropathic pain evoked by the neurotoxic adverse reactions of different anticancer drugs like oxaliplatin, paclitaxel and vincristine. In addition, the pain-relieving effect of D16F7 was demonstrated after local (i.t.) and systemic (i.p.) administration. D16F7 mAb is able to inhibit VEGFR-1 homodimerization, auto-phosphorylation and downstream signal transduction (Graziani *et al*, 2016; Atzori *et al*, 2017, 2018) and down-modulates membrane receptor signaling without affecting VEGF-A or PlGF binding (Graziani *et al*, 2016; Lacal & Graziani, 2018). Indeed, D16F7 mAb interacts with a receptor site corresponding to amino acids 149-161 of human VEGFR-1, which is different from that involved in VEGF-A or PlGF binding (Davis-Smyth *et al*, 1998; Christinger *et al*, 2004; Graziani *et al*, 2016).

CINP is one of the most common adverse events of several first-line chemotherapeutic agents, affecting several million patients worldwide each year and reducing the benefits of effective anticancer therapies in the long-term outcome. It is not possible to predict which patients will develop symptoms and when during the chemotherapy course. Moreover, pain and sensory abnormalities may persist for months, or even years after the cessation of chemotherapy (Argyriou *et al*, 2012; Kolb *et al*, 2016). The management of chemotherapy-induced neuropathy is a

significant challenge and there are no drugs approved to prevent or alleviate CINP (Ibrahim & Ehrlich, 2020). In this scenario, VEGF-A is candidate to be a possible plasmatic biomarker (Di Cesare Mannelli *et al*, 2018) strictly related to pain and the selective blockade of VEGFR-1 may offer the safety qualities requested for the pharmacological treatment of cancer patients in the presence of a possible co-treatment with chemotherapy. In fact, VEGFR-1 is mostly involved in pathological processes rather than in physiological conditions (reviewed in Lacal and Graziani) (Lacal & Graziani, 2018) and in preclinical *in vivo* studies repeated dosing schedules did not cause significant adverse effects, both as single agent or in combination with immune checkpoint inhibitors (Graziani *et al*, 2016; Atzori *et al*, 2018; Ceci *et al*, 2020; Lacal, Pedro Miguel, Atzori, MG; Ruffini, F; Scimeca, M; Bonanno, E; Cicconi, R; Mattei, M; Bernardini, R; D'Atri, S; Tentori, L; Graziani, G, 2020). Interestingly, D16F7 mAb has shown activity in orthotopic *in vivo* models of two highly aggressive tumors: melanoma and glioblastoma (Graziani *et al*, 2016; Atzori *et al*, 2017, 2018). D16F7 efficacy against glioblastoma indicates that therapeutic concentrations of the mAb are reached at the CNS level after systemic administration (Atzori *et al*, 2018). Since VEGFR-1 is expressed not only in tumor cells but also in cell subsets of tumor microenvironment, its blockade by D16F7 results in: a) inhibition of tumor-associated angiogenesis; b) reduction of myeloid progenitor mobilization and tumor infiltration by M2 macrophages/microglia; c) inhibition of invasiveness and vasculogenic mimicry of VEGFR-1 positive tumor cells (Graziani *et al*, 2016; Atzori *et al*, 2018; Lacal, Pedro Miguel, Atzori, MG; Ruffini, F; Scimeca, M; Bonanno, E; Cicconi, R; Mattei, M; Bernardini, R; D'Atri, S; Tentori, L; Graziani, G, 2020). In conclusion, VEGF-A is a pro-nociceptive molecule that in the CNS activates neuronal firing and induces pain by VEGFR-1 stimulation. Actually, VEGF-A increases during chemotherapy-induced neuropathy, and its release from astrocytes plays a decisive role in CINP development. Moreover, the anti-VEGFR-1 mAb D16F7 is suggested as a promising candidate for the treatment of CINP, adding this property to its previously described anti-tumour efficacy. The results of this proof of concept study encourage further investigation on the most effective therapeutic schedule for a long-term pain control.

Materials and Methods

Study approval

All animal manipulations were carried out according to the Directive 2010/63/EU of the European parliament and of the European Union council (22 September 2010) on the protection of animals used for scientific purposes and with IASP. The ethical policy of the University of Florence complies with the Guide for the Care and Use of Laboratory Animals of the US National Institutes

of Health (NIH Publication No. 85-23, revised 1996; University of Florence assurance number: A5278-01). Formal approval to conduct the experiments described was obtained from the Italian Ministry of Health (No. 171/2018-PR) and from the Animal Subjects Review Board of the University of Florence and from the Animal Ethics Committee of University of Campania of Naples. Experiments involving animals have been reported according to ARRIVE guidelines (McGrath & Lilley, 2015). All efforts were made to minimize animal suffering and to reduce the number of animals used.

Animals

Eight week old male CD-1 mice (Envigo, Varese, Italy) weighing 20-25 g at the beginning of the experimental procedure were used. Animals were housed in the Centro Stabulazione Animali da Laboratorio (University of Florence, Italy) and in Stabulario Centralizzato di Ateneo (University of Campania “Luigi Vanvitelli”, Naples, Italy) and used at least 1 week after their arrival. Ten mice were housed per cage (size 26 cm x 41 cm); animals were fed a standard laboratory diet and tap water ad libitum and kept at 23 ± 1 °C with a 12 h light/dark cycle (light at 7 am).

Treatments

VEGF_{165b} (3 – 30 ng; 5 µl; cat. #3045-VE-025, R&D System, USA), PlGF-2 (3 – 30 ng; 5 µl; cat. 465-PL/CF, R&D System, USA), VEGF-E (3 – 30 ng; 5 µl; cat. #CYT-263, Prospecc, Israel), D16F7 (10 - 100 ng, 5 µg; 5 µl) (Graziani *et al.*, 2016) and DC101 (100 pg, 1 – 6 ng; 5 µl; catalog. #BE0060 BioCell, Boston, MA, USA) or vehicle (0.9% NaCl 5 µl) were injected i.t in conscious mice as previously described (Hylden & Wilcox, 1980). Briefly, a 25-µl Hamilton syringe connected to a 30-gauge needle was intervertebral inserted between the L4 and L5 region, and advanced 6 mm into the lumbar enlargement of the spinal cord. Behavioural measurements were performed before and 30 min, 1 h, 3 h and 6 h after the administration of compounds. DC101 or D16F7 were injected 15 min before the VEGFR-1/2 agonists when administered in the co-treatment experiments.

The scrambled siRNA or the specific VEGFR siRNA (VEGFR-1-VEGFR-2 siRNA, Ambion Life Technologies, Monza, Italy) were intrathecally (i.t.) injected twice spaced 24 h apart (3.3 µg/5 µl per mouse) at the lumbar level of the mice spinal cord. On the third day, behavioural measurements were conducted after VEGFRs agonists administration. Mice were sacrificed between the 4th and the 5th days for the western blot analysis. The target sequences of the anti-mouse VEGFRs siRNAs were: VEGFR-1, sense strand 5'-GCAUCUAUAAGGCAGCGGAtt-3' and antisense strand UCCGCUGCCUUAUAGAUGCtc-3'; VEGFR-2, sense strand 5'-

506 CCCGUAUGCUUGUAAAGAAAtt-3' and antisense strand 5'-UUCUUUACAAGCAUACGGGct-
507 3'.

508

509 *AAV virus infection*

510 An AAV1-GFAP-eGFP-mVEGFA-shRNAmir (1.6 X 10¹³ GC/ml, Vector Biosystem Inc,
511 Malvern, PA, USA) or scrambled were used. Mice were deeply anaesthetized by intraperitoneal
512 (i.p.) injection of ketamine (100 mg kg⁻¹) (Ketavet, MSD Animal Health, Milan, Italy) and xylazine
513 (10 mg kg⁻¹) (Rompum, 20 mg/ml, Bayer, Milan, Italy) and then were placed in a stereotaxic frame
514 using the mouse spinal adaptor (Stoelting, Wood Dale, IL, USA). The skin was incised at Th12–L5
515 and the mouse muscles around the left side of the interspace between Th12 - L1 and L4 - L5
516 vertebrae were removed and the dura mater and the arachnoid membrane were carefully incised
517 using the tip of a 30G needle to make a small window to allow vector infusion. Intraspinal
518 injections were done using a 5-μl Hamilton syringe connected to a 34G needle. The needle was
519 placed 0.5 mm lateral to the spinal midline at a depth of 0.4 mm from the dorsal surface of the
520 spinal cord and 1 μl of vector or scrambled was bilaterally injected at 0.25 μl/min with a digital
521 microinjector (Stoelting). The needle was left on place for another 3 min to prevent backflow. The
522 surgical site was then sutured with 3-0 silk and mice were kept on a heating pad until recovery.

523

524 *CINP in vivo models*

525 Mice treated with oxaliplatin (Carbosynth, Pangbourne, UK; 2.4 mg kg⁻¹) were administered i.p. for
526 two weeks (Cavaletti *et al*, 2001; Di Cesare Mannelli *et al*, 2017). Oxaliplatin was dissolved in a
527 5% glucose solution. Control animals received an equivalent volume of vehicle. Behavioural tests
528 were performed on day 15 for the acute treatments. In mice injected spinally with the viral vector or
529 with the scrambled, oxaliplatin was administered for two weeks (10 total injections) starting 14
530 days after surgery for the viral vector administration. Control animals received an equivalent
531 volume of vehicle. Behavioural measurements were performed on days 3, 5, 9, 11, 13 and 15.

532 Mice treated with paclitaxel (Carbosynth; 2.0 mg kg⁻¹) were injected i.p. on four alternate days
533 (days 1, 3, 5 and 8) (Polomano *et al*, 2001; Di Cesare Mannelli *et al*, 2017). Paclitaxel was
534 dissolved in a mixture of 10% saline solution and Cremophor EL, a derivative of castor oil and
535 ethylene oxide that is clinically used as paclitaxel vehicle. Control animals received an equivalent
536 volume of vehicle. Behavioural measurements started on day 10.

537 Mice treated with vincristine (Carbosynth; 0.1 mg kg⁻¹) were injected i.p. for five consecutive days
538 (Weng *et al*, 2003). Vincristine was dissolved in saline solution and control animals received an
539 equivalent volume of vehicle. Behavioural measurements started on day 8.

Assessment of mechanical hyperalgesia (Paw pressure test)

Mechanical hyperalgesia was determined by measuring the latency in seconds to withdraw the paw away from a constant mechanical pressure exerted onto the dorsal surface (Russo *et al*, 2012; Lucarini *et al*, 2019). A 15 g calibrated glass cylindrical rod (10 mm diameter) chamfered to a conical point (3 mm diameter) was used to exert the mechanical force. The weight was suspended vertically between two rings attached to a stand and was free to move vertically. A single measure was made per animal. A cut-off time of 40 s was used.

Assessment of thermal allodynia (Cold plate test)

Thermal allodynia was assessed using the Cold-plate test. With minimal animal-handler interaction, mice were taken from home-cages, and placed onto the surface of the cold-plate (Ugo Basile, Varese, Italy) maintained at a constant temperature of $4^{\circ}\text{C} \pm 1^{\circ}\text{C}$. Ambulation was restricted by a cylindrical plexiglas chamber (diameter: 10 cm, height: 15 cm), with open top. A timer controlled by foot peddle began timing response latency from the moment the mouse was placed onto the cold-plate. Pain-related behaviour (licking of the hind paw) was observed, and the time (seconds) of the first sign was recorded. The cut-off time of the latency of paw lifting or licking was set at 30 s (Baptista-de-Souza *et al*, 2014).

Assessment of mechanical allodynia (Von Frey test)

Mechanical allodynia was measured with the dynamic plantar aesthesiometer (von Frey instrument) (Ugo Basile) as described by Di Cesare Mannelli and colleagues (Di Cesare Mannelli *et al*, 2017) with minor modifications. Briefly, the mice were placed in individual Plexiglas cubicles ($8.5 \times 3.4 \times 3.4$ cm) on a wire mesh platform. After approximately 30 min accommodation period, during which exploratory and grooming activity ended, the mechanical paw withdrawal threshold was measured as the hind paw withdrawal responded to von Frey hair stimulation. The mechanical stimulus was delivered to the plantar surface of the hind paw of the mouse from below the floor of the test chamber by an automated testing device. A steel rod (2 mm) was pushed with electronic ascending force (0–5 g in 35 s). When the animal withdrew its hind paw, the mechanical stimulus was automatically withdrawn, and the force recorded to the nearest 0.1 g. Nociceptive response for mechanical sensitivity was expressed as mechanical withdrawal threshold in grams. The mean was calculated from six consecutive trials and averaged for each group of mice.

Assessment of locomotor activity (Hole-Board test)

The locomotor activity was evaluated by using the hole-board test. The apparatus consisted of a 40 cm square plane with 16 flush mounted cylindrical holes (3 cm diameter) distributed 4×4 in an equidistant, grid-like manner. Mice were placed on the centre of the board one by one and allowed to move about freely for a period of 5 min each. Two photobeams, crossing the plane from mid-point to mid-point of opposite sides, thus dividing the plane into 4 equal quadrants, automatically signalled the movement of the animal (counts in 5 min) on the surface of the plane (locomotor activity). Miniature photoelectric cells, in each of the 16 holes, recorded (counts in 5 min) the exploration of the holes (exploratory activity) by the mice (Ghelardini *et al*, 2002).

Electrophysiological recordings of nociceptive specific (NS) neurons

On the day of electrophysiological recordings, mice were initially anesthetized with tribromoethanol (Avertin, Winthrop laboratories, New York, NY, USA; 1.25%). After tracheal cannulation, a catheter was placed into the right external jugular vein, to allow continuous infusion of propofol (5–10 mg/kg/h, i.v.) and spinal cord segments L4-L6 were exposed by laminectomy, near the dorsal root entry zone, up to a depth of 1 mm (McGaraughty *et al*, 2010). An elliptic rubber ring (about 3×5 mm), sealed with silicone gel onto the surface of the cord, was used for topical spinal drug application and to gain access to spinal neurons. Animals were fixed in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA) through clamps attached to the vertebral processes. Single unit extracellular activity of dorsal horn NS neurons was performed by using a glass-insulated tungsten filament electrode (3–5 MΩ) (FHC Frederick Haer & Co., ME, USA). Spinal neurons were defined as NS neurons, when they were responding only to high intensity (noxious) stimulation (Telleria-Diaz *et al*, 2010). In particular, to confirm NS response patterns, each neuron was characterized by applying a mechanical stimulation to the ipsilateral hind paw using a von Frey filament with 97.8 mN bending force (noxious stimulation) for 2 s until it buckled slightly (Boccella *et al*, 2015; Simone *et al*, 2008). Only neurons that specifically responded to noxious hind paw stimulation were considered for recordings. The recorded signals were visualized into a window discriminator, whose output was processed by an interface CED 1401 (Cambridge Electronic Design Ltd., UK) connected to iOS 5 PC. Spike2 software (CED, version 5) was used to create peristimulus rate histograms on-line and to store and analyze digital records of single unit activity off-line. The spontaneous and noxious-evoked neuronal activity was expressed as spikes/sec (Hz) and the effect of drugs was analyzed as % variation of firing rate, frequency and duration of excitation. After recording a stable basal activity (15 min), topical spinal application of vehicle or drugs was performed, and each extracellular recording was monitored until 45-60 min post-injection. In particular, groups of animals were divided as following: 1) VEGF_{165b} (3 ng/5 µl,

pro-nociceptive dose on NS neurons), 2) VEGF₁₆₅b + DC101 (10 pg/5 µl, the highest non pro-nociceptive dose) and 3) VEGF₁₆₅b + D16F7 (100 pg/5 µl). At the end of the experiment, animals were killed with a lethal dose of urethane.

Western blot analysis

The lumbar spinal cord of mice was explanted and immediately frozen with liquid nitrogen. The frozen tissues were homogenized with lysis buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100 and complete protease inhibitors (Roche, Milan, Italy). The suspensions were sonicated on ice using three high intensity 10s bursts with a cooling period of 10s each burst and centrifuged at 13.000xg for 10 min at 4°C. Protein concentrations were quantified by bicinchoninic acid test. Fifty µg of tissue homogenate were resolved with prefabricated polyacrylamide gel (BOLT 4-12% Bis-Tris Plus gel; Thermo Fisher Scientific, Monza, Italy) before electrophoretic transfer to nitrocellulose membranes (Bio-Rad, Milan, Italy). The membranes were blocked with 1% BSA and 5% fat-free powdered milk in PBS containing 0.1% Tween 20 (PBST) and then probed overnight at 4°C with primary antibodies specific for VEGFR-1, VEGFR-2, VEGF-A, GAPDH or α-Tubulin (Supplementary Table S1). The membranes were then incubated for 1 h in PBST containing the appropriate secondary anti-rabbit or anti-mouse antibody (Supplementary Table S1). ECL (Enhanced Chemiluminescence Pierce, Rockford, IL, USA) was used to visualize peroxidase-coated bands. Densitometric analysis was performed using the "ImageJ" analysis software (ImageJ, NIH, Bethesda, MD, USA). Normalization for α-tubulin or GAPDH content was performed. The values were reported as percentages of controls arbitrarily set at 100%.

Immunofluorescence staining and confocal imaging

Mice were sacrificed, the L4/L5 segments of the spinal cord were exposed from the lumbovertebral column via laminectomy and identified by tracing the dorsal roots from their respective DRG. Formalin-fixed (and no-fixed, used for VEGFR-1 primary antibody) cryostat sections (7 µm) were washed 3x phosphate-buffered saline (PBS) and then were incubated, at room temperature for 1 h, in blocking solution (PBS, 0.3% Triton X-100, 5% albumin bovine serum; PBST). The sections were subsequently incubated with primary antibody, anti-VEGFR-1, anti-VEGF-A, or anti-AQP-4, overnight at 4°C (Supplementary Table S1). The following day, slides were washed 3× with PBS and then sections were incubated in the dark with secondary antibody, goat anti-rabbit or anti-mouse IgG labeled with Alexa Fluor 568, in PBST at room temperature for 2 h. After 3× PBS 0.3% Triton X-100 wash for 10 min, the sections were incubated with DAPI, a nuclei-marker, at room

temperature for 5 min and then the slides were mounted using Fluoromount™ (Life Technologies-Thermo scientific, Rockford, IL, USA) as a mounting medium.

For double immunofluorescence, on the first day, anti-Iba1 was added and the slides incubated overnight at 4°C conditions. While, the sections to be labelled for GFAP or NeuN were incubated the second day for 2 h in the dark with mouse anti-GFAP Alexa Fluor 488-conjugated or mouse anti-NeuN Alexa Fluor 488-conjugated antibodies (Supplementary Table S1). For triple immunofluorescence, on the first day, anti-RECA-1 was added and the slides incubated overnight at 4°C conditions, then sections were incubated with the anti-mouse IgG labeled with Alexa Fluor 568 for 2 h. Thereafter, incubation with anti-VEGF-A and anti-GFAP antibodies was allowed overnight in the dark. Finally, anti-mouse IgG labeled with Alexa Fluor 488 and anti-rabbit IgG labeled with Alexa Fluor 647 were added for 2 h in the dark (Supplementary Table S1).

Negative control sections (no exposure to the primary antisera) were processed concurrently with the other sections for all immunohistochemical studies. Images were acquired using a motorized Leica DM6000 B microscope equipped with a DFC350FX camera (Leica, Mannheim, Germany).

The colocalization area was calculated using the "colocalization" plugin of ImageJ (after evaluating the threshold value for each channel) and expressed as percentage relative to the value of the VEGFR-1 or VEGF-A area. The mean fluorescence intensity of VEGF-A in control and oxaliplatin-treated animals was calculated by subtracting the background (multiplied by the total area) from the VEGF-A integrated intensity. Analyses were performed on three different images for each animal, collected through a 20x objective.

For confocal analysis, images were acquired with a Leica SP2 AOBS confocal microscope using a sequential scan setting (exciting lasers 488 nm and 561nm) to avoid channel bleed-through. Images were acquired through a 63x 1.4NA PL APO objective at voxel size of 232nm (xy) and 121nm (z).

Confocal images were processed and analyzed using Fiji (Schindelin *et al*, 2012). Briefly, images were deconvolved using Deconvolution Lab2 with a synthetic PSF and ICTM algorithm (Sage *et al*, 2017). Colocalization analysis was performed with JACoP (Fiji plugin) (Bolte & Cordelières, 2006) and manually set thresholds. Colocalization parameters were calculated from 8 confocal z-stacks for each analysis and are given as mean ± SEM.

Statistics

Results were expressed as means ± SEM and the analysis of variance was performed by ANOVA test. A Bonferroni's significant difference procedure was used as post hoc comparison. P values less than 0.05 were considered significant. Data were analysed using "Origin® 10" software.

Electrophysiological data were analysed through one- way ANOVA followed by Dunnet's multiple comparison post-hoc test for statistical significance within groups. Two-way ANOVA followed by Bonferroni post-hoc test for comparison between groups, by using GraphPad Prism 7.0.

Acknowledgements

The authors are grateful to Prof. D. Salvemini (Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, United States) and to Dr. Warren Glaab (Merck, USA) for their input in our work and for the editorial contribution to the manuscript.

Competing Interests

The authors declare no potential conflicts of interest

Financial Support

This work was supported by the IMI2 project NeuroDerisk (821528), the Italian Ministry of University and Research, the University of Florence, by the Italian Association for Cancer Research (AIRC) under IG 2017 - ID. 20353 project - PI Graziani Grazia, and by the Italian Ministry of Health RC18-2638151 to Pedro M. Lacal.

Author contributions

LM performed treatments, behavioral measurements and drafted the manuscript, EL contributed to behavioral tests and analyzed data, CP, AP, AV and AT performed molecular assay, TM performed confocal analysis, SB, FR and SM performed electrophysiological measurements, GG, PML, SM, PF, AP and CG contributed to plan the study, drafted and revised the manuscript, LDCM conceived the study and drafted the manuscript.

References

- Alles SRA & Smith PA (2018) Etiology and Pharmacology of Neuropathic Pain. *Pharmacol Rev* 70: 315–347
- Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Mariani JN, Mahase S, Dutta DJ, Seto J, Kramer EG, *et al* (2012) Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. *J Clin Invest* 122: 2454–2468
- Argyriou AA, Bruna J, Marmioli P & Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. *Crit Rev Oncol Hematol* 82: 51–77
- Atzori MG, Tentori L, Ruffini F, Ceci C, Bonanno E, Scimeca M, Lacal PM & Graziani G (2018)

708 The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7
709 Inhibits Glioma Growth and Angiogenesis In Vivo. *J Pharmacol Exp Ther* 364: 77–86

710 Atzori MG, Tentori L, Ruffini F, Ceci C, Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T,
711 Miletic H, *et al* (2017) The anti-vascular endothelial growth factor receptor-1 monoclonal
712 antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. *J*
713 *Exp Clin Cancer Res* 36: 106

714 Baptista-de-Souza D, Di Cesare Mannelli L, Zanardelli M, Micheli L, Nunes-de-Souza RL, Canto-
715 de-Souza A & Ghelardini C (2014) Serotonergic modulation in neuropathy induced by
716 oxaliplatin: effect on the 5HT2C receptor. *Eur J Pharmacol* 735: 141–149

717 Beazley-Long N, Hua J, Jehle T, Hulse RP, Dersch R, Lehring C, Bevan H, Qiu Y, Lagrèze WA,
718 Wynick D, *et al* (2013) VEGF-A165b Is an Endogenous Neuroprotective Splice Isoform of
719 Vascular Endothelial Growth Factor A in Vivo and in Vitro. *Am J Pathol* 183: 918–929

720 Boccella S, Vacca V, Errico F, Marinelli S, Squillace M, Guida F, Di Maio A, Vitucci D, Palazzo
721 E, De Novellis V, *et al* (2015) D-Aspartate Modulates Nociceptive-Specific Neuron Activity
722 and Pain Threshold in Inflammatory and Neuropathic Pain Condition in Mice. *Biomed Res Int*
723 2015: 1–10

724 Bolte S & Cordelières FP (2006) A guided tour into subcellular colocalization analysis in light
725 microscopy. *J Microsc* 224: 213–232

726 Branca JJV, Maresca M, Morucci G, Becatti M, Paternostro F, Gulisano M, Ghelardini C,
727 Salvemini D, Di Cesare Mannelli L & Pacini A (2018) Oxaliplatin-induced blood brain barrier
728 loosening: a new point of view on chemotherapy-induced neurotoxicity. *Oncotarget* 9: 23426–
729 23438

730 Cai M, Wang K, Murdoch CE, Gu Y & Ahmed A (2017) Heterodimerisation between VEGFR-1
731 and VEGFR-2 and not the homodimers of VEGFR-1 inhibit VEGFR-2 activity. *Vascul*
732 *Pharmacol* 88: 11–20

733 Cavaletti G, Tredici G, Petruccioli MG, Dondè E, Tredici P, Marmiroli P, Minoia C, Ronchi A,
734 Bayssas M & Etienne GG (2001) Effects of different schedules of oxaliplatin treatment on the
735 peripheral nervous system of the rat. *Eur J Cancer* 37: 2457–2463

736 Ceci C, Atzori MG, Lacal PM & Graziani G (2020) Role of VEGFs/VEGFR-1 Signaling and its
737 Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic
738 Cancer Models. *Int J Mol Sci* 21

739 Di Cesare Mannelli L, Lucarini E, Micheli L, Mosca I, Ambrosino P, Soldovieri MV, Martelli A,
740 Testai L, Taglialatela M, Calderone V, *et al* (2017) Effects of natural and synthetic
741 isothiocyanate-based H₂S-releasers against chemotherapy-induced neuropathic pain: Role of

742 Kv7 potassium channels. *Neuropharmacology* 121: 49–59

743 Di Cesare Mannelli L, Marcoli M, Micheli L, Zanardelli M, Maura G, Ghelardini C & Cervetto C
744 (2015) Oxaliplatin evokes P2X7-dependent glutamate release in the cerebral cortex: A pain
745 mechanism mediated by Pannexin 1. *Neuropharmacology* 97: 133–141

746 Di Cesare Mannelli L, Pacini A, Bonaccini L, Zanardelli M, Mello T & Ghelardini C (2013)
747 Morphologic Features and Glial Activation in Rat Oxaliplatin-Dependent Neuropathic Pain. *J*
748 *Pain* 14: 1585–1600

749 Di Cesare Mannelli L, Pacini A, Micheli L, Tani A, Zanardelli M & Ghelardini C (2014) Glial role
750 in oxaliplatin-induced neuropathic pain. *Exp Neurol* 261: 22–33

751 Di Cesare Mannelli L, Tenci B, Micheli L, Vona A, Corti F, Zanardelli M, Lapucci A, Clemente
752 AM, Failli P & Ghelardini C (2018) Adipose-derived stem cells decrease pain in a rat model of
753 oxaliplatin-induced neuropathy: Role of VEGF-A modulation. *Neuropharmacology* 131: 166–
754 175

755 Chapouly C, Tadesse Argaw A, Horng S, Castro K, Zhang J, Asp L, Loo H, Laitman BM, Mariani
756 JN, Straus Farber R, *et al* (2015) Astrocytic TYMP and VEGFA drive blood–brain barrier
757 opening in inflammatory central nervous system lesions. *Brain* 138: 1548–1567

758 Christinger HW, Fuh G, de Vos AM & Wiesmann C (2004) The Crystal Structure of Placental
759 Growth Factor in Complex with Domain 2 of Vascular Endothelial Growth Factor Receptor-1.
760 *J Biol Chem* 279: 10382–10388

761 Cudmore MJ, Hewett PW, Ahmad S, Wang K-Q, Cai M, Al-Ani B, Fujisawa T, Ma B, Sissaoui S,
762 Ramma W, *et al* (2012) The role of heterodimerization between VEGFR-1 and VEGFR-2 in
763 the regulation of endothelial cell homeostasis. *Nat Commun* 3: 972

764 Davis-Smyth T, Presta LG & Ferrara N (1998) Mapping the Charged Residues in the Second
765 Immunoglobulin-like Domain of the Vascular Endothelial Growth Factor/Placenta Growth
766 Factor Receptor Flt-1 Required for Binding and Structural Stability. *J Biol Chem* 273: 3216–
767 3222

768 Failla C, Carbo M & Morea V (2018) Positive and Negative Regulation of Angiogenesis by Soluble
769 Vascular Endothelial Growth Factor Receptor-1. *Int J Mol Sci* 19: 1306

770 Falcon BL, Chintharlapalli S, Uhlik MT & Pytowski B (2016) Antagonist antibodies to vascular
771 endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. *Pharmacol Ther*
772 164: 204–225

773 Garraway SM & Huie JR (2016) Spinal Plasticity and Behavior: BDNF-Induced Neuromodulation
774 in Uninjured and Injured Spinal Cord. *Neural Plast* 2016: 1–19

775 Ghelardini C, Galeotti N, Calvani M, Mosconi L, Nicolai R & Bartolini A (2002) Acetyl-L-carnitine

776 induces muscarinic antinociception in mice and rats. *Neuropharmacology* 43: 1180–1187

777 Graziani G, Ruffini F, Tentori L, Scimeca M, Dorio AS, Atzori MG, Failla CM, Morea V, Bonanno

778 E, D’Atri S, *et al* (2016) Antitumor activity of a novel anti-vascular endothelial growth factor

779 receptor-1 monoclonal antibody that does not interfere with ligand binding. *Oncotarget* 7:

780 72868–72885

781 Hamilton JL, Nagao M, Levine BR, Chen D, Olsen BR & Im H-J (2016) Targeting VEGF and Its

782 Receptors for the Treatment of Osteoarthritis and Associated Pain: TARGETING VEGF AND

783 VEGFRs FOR TREATMENT OF OSTEOARTHRITIS AND PAIN. *J Bone Miner Res* 31:

784 911–924

785 Hu X-M, Yang W, Du L-X, Cui W-Q, Mi W-L, Mao-Ying Q-L, Chu Y-X & Wang Y-Q (2019)

786 Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and

787 Pain-related Behaviors in Female Rats with Bone Cancer. *Anesthesiology* 131: 1125–1147

788 Hulse RP, Beazley-Long N, Hua J, Kennedy H, Prager J, Bevan H, Qiu Y, Fernandes ES,

789 Gammons M V, Ballmer-Hofer K, *et al* (2014) Regulation of alternative VEGF-A mRNA

790 splicing is a therapeutic target for analgesia. *Neurobiol Dis* 71: 245–259

791 Hylden JLK & Wilcox GL (1980) Intrathecal morphine in mice: A new technique. *Eur J Pharmacol*

792 67: 313–316

793 Ibrahim EY & Ehrlich BE (2020) Prevention of chemotherapy-induced peripheral neuropathy: A

794 review of recent findings. *Crit Rev Oncol Hematol* 145: 102831

795 Iyer S & Acharya KR (2011) Tying the knot: The cystine signature and molecular-recognition

796 processes of the vascular endothelial growth factor family of angiogenic cytokines: Cystine-

797 knot growth factors and angiogenesis. *FEBS J* 278: 4304–4322

798 Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S & Mooney K (2016) The

799 Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of

800 Falling. *JAMA Neurol* 73: 860

801 Lacal, Pedro Miguel, Atzori, MG; Ruffini, F; Scimeca, M; Bonanno, E; Cicconi, R; Mattei, M;

802 Bernardini, R; D’Atri, S; Tentori, L; Graziani, G (2020) Targeting the vascular endothelial

803 growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of

804 immune checkpoint inhibitors against cutaneous melanoma. *Pharmacol Res*

805 Lacal PM & Graziani G (2018) Therapeutic implication of vascular endothelial growth factor

806 receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive

807 and non-competitive inhibitors. *Pharmacol Res* 136: 97–107

808 Lange C, Storkebaum E, de Almodóvar CR, Dewerchin M & Carmeliet P (2016) Vascular

809 endothelial growth factor: a neurovascular target in neurological diseases. *Nat Rev Neurol* 12:

810 439–454

811 Lee GW, Son JY, Lee AR, Ju JS, Bae YC & Ahn DK (2019) Central VEGF-A pathway plays a key
812 role in the development of trigeminal neuropathic pain in rats. *Mol Pain* 15: 174480691987260

813 Licht T & Keshet E (2013) Delineating multiple functions of VEGF-A in the adult brain. *Cell Mol*
814 *Life Sci* 70: 1727–1737

815 Lin J, Li G, Den X, Xu C, Liu S, Gao Y, Liu H, Zhang J, Li X & Liang S (2010) VEGF and its
816 receptor-2 involved in neuropathic pain transmission mediated by P2X₂(/)₃ receptor of
817 primary sensory neurons. *Brain Res Bull* 83: 284–291

818 Lucarini E, Pagnotta E, Micheli L, Parisio C, Testai L, Martelli A, Calderone V, Matteo R, Lazzeri
819 L, Di Cesare Mannelli L, *et al* (2019) Eruca sativa Meal against Diabetic Neuropathic Pain: An
820 H(2)S-Mediated Effect of Glucoerucin. *Molecules* 24

821 McGaraughty S, Chu KL, Perner RJ, Didomenico S, Kort ME & Kym PR (2010) TRPA1
822 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured,
823 osteoarthritic, and inflamed rats. *Mol Pain* 6: 14

824 McGrath JC & Lilley E (2015) Implementing guidelines on reporting research using animals
825 (ARRIVE etc.): new requirements for publication in BJP. *Br J Pharmacol* 172: 3189–3193

826 Meyer M (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E,
827 mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1)
828 receptor tyrosine kinases. *EMBO J* 18: 363–374

829 Miltenburg NC & Boogerd W (2014) Chemotherapy-induced neuropathy: A comprehensive survey.
830 *Cancer Treat Rev* 40: 872–882

831 Montague-Cardoso K, Pitcher T, Chisolm K, Salera G, Lindstrom E, Hewitt E, Solito E &
832 Malcangio M (2020) Changes in vascular permeability in the spinal cord contribute to
833 chemotherapy-induced neuropathic pain. *Brain Behav Immun* 83: 248–259

834 Nakayama M, Nakayama A, van Lessen M, Yamamoto H, Hoffmann S, Drexler HCA, Itoh N,
835 Hirose T, Breier G, Vestweber D, *et al* (2013) Spatial regulation of VEGF receptor
836 endocytosis in angiogenesis. *Nat Cell Biol* 15: 249–260

837 Nencini S, Ringuet M, Kim D-H, Greenhill C & Ivanusic JJ (2018) GDNF, Neurturin, and Artemin
838 Activate and Sensitize Bone Afferent Neurons and Contribute to Inflammatory Bone Pain. *J*
839 *Neurosci* 38: 4899–4911

840 Park JE, Chen HH, Winer J, Houck KA & Ferrara N (1994) Placenta growth factor. Potentiation of
841 vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to
842 Flt-1 but not to Flk-1/KDR. *J Biol Chem* 269: 25646–25654

843 Peach C, Mignone V, Arruda M, Alcobia D, Hill S, Kilpatrick L & Woolard J (2018) Molecular

844 Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. *Int J Mol Sci* 19:
845 1264

846 Persico MG, Vincenti V & DiPalma T (1999) Structure, Expression and Receptor-Binding
847 Properties of Placenta Growth Factor (PlGF). In *Vascular Growth Factors and Angiogenesis*,
848 Claesson-Welsh L (ed) pp 31–40. Berlin, Heidelberg: Springer Berlin Heidelberg

849 Polomano RC, Mannes AJ, Clark US & Bennett GJ (2001) A painful peripheral neuropathy in the
850 rat produced by the chemotherapeutic drug, paclitaxel: *Pain* 94: 293–304

851 Ponnambalam S & Alberghina M (2011) Evolution of the VEGF-Regulated Vascular Network from
852 a Neural Guidance System. *Mol Neurobiol* 43: 192–206

853 Rojas DR, Tegeder I, Kuner R & Agarwal N (2018) Hypoxia-inducible factor 1 α protects peripheral
854 sensory neurons from diabetic peripheral neuropathy by suppressing accumulation of reactive
855 oxygen species. *J Mol Med* 96: 1395–1405

856 Ruiz de Almodovar C, Lambrechts D, Mazzone M & Carmeliet P (2009) Role and Therapeutic
857 Potential of VEGF in the Nervous System. *Physiol Rev* 89: 607–648

858 Russo R, D’Agostino G, Mattace Raso G, Avagliano C, Cristiano C, Meli R & Calignano A (2012)
859 Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid
860 and opioid systems. *Peptides* 38: 81–88

861 Sage D, Donati L, Soulez F, Fortun D, Schmit G, Seitz A, Guiet R, Vonesch C & Unser M (2017)
862 DeconvolutionLab2: An open-source software for deconvolution microscopy. *Methods* 115:
863 28–41

864 Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden
865 C, Saalfeld S, Schmid B, *et al* (2012) Fiji: an open-source platform for biological-image
866 analysis. *Nat Methods* 9: 676–682

867 Scholz J & Woolf CJ (2007) The neuropathic pain triad: neurons, immune cells and glia. *Nat*
868 *Neurosci* 10: 1361–1368

869 Schratzberger P, Schratzberger G, Silver M, Curry C, Kearney M, Magner M, Alroy J, Adelman
870 LS, Weinberg DH, Ropper AH, *et al* (2000) Favorable effect of VEGF gene transfer on
871 ischemic peripheral neuropathy. *Nat Med* 6: 405–413

872 Seki T, Hosaka K, Fischer C, Lim S, Andersson P, Abe M, Iwamoto H, Gao Y, Wang X, Fong G-
873 H, *et al* (2018) Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing
874 adipose tissue browning. *J Exp Med* 215: 611–626

875 Selvaraj D, Gangadharan V, Michalski CW, Kurejova M, Stösser S, Srivastava K, Schweizerhof M,
876 Waltenberger J, Ferrara N, Heppenstall P, *et al* (2015) A Functional Role for VEGFR1
877 Expressed in Peripheral Sensory Neurons in Cancer Pain. *Cancer Cell* 27: 780–796

878 Simone DA, Khasabov SG & Hamamoto DT (2008) Changes in response properties of nociceptive
879 dorsal horn neurons in a murine model of cancer pain. *Sheng Li Xue Bao* 60: 635–644

880 Sommer C, Leinders M & Üçeyler N (2018) Inflammation in the pathophysiology of neuropathic
881 pain: *Pain* 159: 595–602

882 Stevens M & Oltean S (2018) Modulation of VEGF-A Alternative Splicing as a Novel Treatment in
883 Chronic Kidney Disease. *Genes (Basel)* 9: 98

884 Stockstill K, Doyle TM, Yan X, Chen Z, Janes K, Little JW, Braden K, Lauro F, Giancotti LA,
885 Harada CM, *et al* (2018) Dysregulation of sphingolipid metabolism contributes to bortezomib-
886 induced neuropathic pain. *J Exp Med* 215: 1301–1313

887 Taiana MM, Lombardi R, Porretta-Serapiglia C, Ciusani E, Oggioni N, Sassone J, Bianchi R &
888 Lauria G (2014) Neutralization of Schwann Cell-Secreted VEGF Is Protective to In Vitro and
889 In Vivo Experimental Diabetic Neuropathy. *PLoS One* 9: e108403

890 Telleria-Diaz A, Schmidt M, Kreusch S, Neubert A-K, Schache F, Vazquez E, Vanegas H, Schaible
891 H-G & Ebersberger A (2010) Spinal antinociceptive effects of cyclooxygenase inhibition
892 during inflammation: Involvement of prostaglandins and endocannabinoids: *Pain* 148: 26–35

893 Ved N, Da Vitoria Lobo ME, Bestall SM, L. Vidueira C, Beazley-Long N, Ballmer-Hofer K,
894 Hirashima M, Bates DO, Donaldson LF & Hulse RP (2018) Diabetes-induced microvascular
895 complications at the level of the spinal cord: a contributing factor in diabetic neuropathic pain:
896 Diabetes-induced microvascular degeneration and neuropathic pain. *J Physiol* 596: 3675–3693

897 Verheyen A, Peeraer E, Lambrechts D, Poesen K, Carmeliet P, Shibuya M, Pintelon I, Timmermans
898 J-P, Nuydens R & Meert T (2013) Therapeutic potential of VEGF and VEGF-derived peptide
899 in peripheral neuropathies. *Neuroscience* 244: 77–89

900 Verheyen A, Peeraer E, Nuydens R, Dhondt J, Poesen K, Pintelon I, Daniels A, Timmermans J-P,
901 Meert T, Carmeliet P, *et al* (2012) Systemic anti-vascular endothelial growth factor therapies
902 induce a painful sensory neuropathy. *Brain* 135: 2629–2641

903 Weng -R H, Cordella VJ & Dougherty MP (2003) Changes in sensory processing in the spinal
904 dorsal horn accompany vincristine-induced hyperalgesia and allodynia: *Pain* 103: 131–138

905 Woolard J, Wang W-Y, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui T-G, Sugiono M,
906 Waine E, Perrin R, *et al* (2004) VEGF₁₆₅ b, an Inhibitory Vascular Endothelial Growth Factor
907 Splice Variant: Mechanism of Action, **In vivo** Effect On Angiogenesis and Endogenous
908 Protein Expression. *Cancer Res* 64: 7822–7835